The Life Sciences team advised Kaleido Biosciences (Nasdaq: KLDO) on its $35.6 million public offering of 4,750,000 shares of its common stock at a public offering price of $7.50 per share, including a 30-day option for underwriters to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions.
Kaleido is a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health.
The Goodwin team was led by Kingsley Taft, and Kim Larie, and included Dan Karelitz, Ettore Santucci, and Nathan Needle.
For more details, read the press release and articles in Street Insider, Reuters, and Seeking Alpha.
Kaleido is a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health.
The Goodwin team was led by Kingsley Taft, and Kim Larie, and included Dan Karelitz, Ettore Santucci, and Nathan Needle.
For more details, read the press release and articles in Street Insider, Reuters, and Seeking Alpha.